|
[1] BULLOCK M. FOXO factors and breast cancer:Outfoxing endocrine resistance[J]. Endocr Relat Cancer, 2016, 23 (2) :113-130.
|
|
[2] WEIGEL D, JURGENS G, KUTTNER F, et al. The homeotic gene fork head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo[J]. Cell, 1989, 57 (4) :645-658.
|
|
[3] KUMAZOE M, TAKAI M, BAE J, et al. FOXO3 is essential for CD44 expression in pancreatic cancer cells[J]. Oncogene, 2017, 36 (19) :2643-2654.
|
|
[4] WILHELM K, HAPPEL K, EELEN G, et al. FOXO1 couples metabolic activity and growth state in the vascular endothelium[J]. Nature, 2016, 529 (7585) :216-220.
|
|
[5] DAS SK, DESAULNIERS J, DYCK JR, et al. Resveratrol mediates therapeutic hepatic effects in acquired and genetic murine models of iron-overload[J]. Liver Int, 2016, 36 (2) :246-257.
|
|
[6] de MAGALHAES JP, WUTTKE D, WOOD SH, et al. Genomeenvironment interactions that modulate aging:Powerful targets for drug discovery[J]. Pharmacol Rev, 2012, 64 (1) :88-101.
|
|
[7] SALMINEN A, KAARNIRANTA K, KAUPPINEN A. Age-related changes in AMPK activation:Role for AMPK phosphatases and inhibitory phosphorylation by upstream signaling pathways[J]. Ageing Res Rev, 2016, 28:15-26.
|
|
[8] NANTHAKUMAR CB, HATLEY RJ, LEMMA S, et al. Dissecting fibrosis:Therapeutic insights from the small-molecule toolbox[J]. Nat Rev Drug Discov, 2015, 14 (10) :693-720.
|
|
[9] ROCKEY DC, BELL PD, HILL JA. Fibrosis—a common pathway to organ injury and failure[J]. N Engl J Med, 2015, 372 (12) :1138-1149.
|
|
[10] MARTIN K, PRITCHETT J, LLEWELLYN J, et al. PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis[J]. Nat Commun, 2016, 7:12502.
|
|
[11] GRESSNER OA, RIZK MS, KOVALENKO E, et al. Changing the pathogenetic roadmap of liver fibrosis? Where did it start;where will it go?[J]. J Gastroenterol Hepatol, 2008, 23 (7 Pt1) :1024-1035.
|
|
[12] LI Y, LU LG. Molecular basis of hepatic fibrosis and current status of its diagnosis and treatment[J]. J Clin Hepatol, 2018, 34 (1) :12-15. (in Chinese) 李妍, 陆伦根.肝纤维化的分子基础与临床诊治现状[J].临床肝胆病杂志, 2018, 34 (1) :12-15.
|
|
[13] ZHANG W, JIA JD. Pathogenesis and new therapeutic targets of liver fibrosis[J]. J Clin Hepatol, 2017, 33 (3) :409-412. (in Chinese) 张伟, 贾继东.肝纤维化的发病机制及治疗新靶点[J].临床肝胆病杂志, 2017, 33 (3) :409-412.
|
|
[14] SAITO I, SARUTA T. Therapeutic drug monitoring of inhibitors of renin-angiotensin system[J]. Nihon Rinsho, 1990, 48 (Suppl) :1146-1148.
|
|
[15] BENTEN D, KUMARAN V, JOSEPH B, et al. Hepatocyte transplantation activates hepatic stellate cells with beneficial modulation of cell engraftment in the rat[J]. Hepatology, 2005, 42 (5) :1072-1081.
|
|
[16] XU MY, HU JJ, SHEN J, et al. Stat3 signaling activation crosslinking of TGF-beta1 in hepatic stellate cell exacerbates liver injury and fibrosis[J]. Biochim Biophys Acta, 2014, 1842 (11) :2237-2245.
|
|
[17] CAI W, ZHAO L, LI HR, et al. Influence of kaempferol on TGF-beta1/Smads signal path in liver tissue of mice with Schistosoma japonicum infection[J]. Chin J Schi Contl, 2014, 26 (4) :399-404, 419. (in Chinese) 蔡文, 赵雷, 李华蓉, 等.山奈酚对感染日本血吸虫小鼠TGF-β1/Smads信号通路的影响[J].中国血吸虫病防治杂志, 2014, 26 (4) :399-404, 419.
|
|
[18] CUTRONEO KR. TGF-beta-induced fibrosis and SMAD signaling:Oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring[J]. Wound Repair Regen, 2007, 15 (Suppl 1) :s54-s60.
|
|
[19] HEMMANN S, GRAF J, RODERFELD M, et al. Expression of MMPs and TIMPs in liver fibrosis-a systematic review with special emphasis on anti-fibrotic strategies[J]. J Hepatol, 2007, 46 (5) :955-975.
|
|
[20] BREW K, NAGASE H. The tissue inhibitors of metalloproteinases (TIMPs) :An ancient family with structural and functional diversity[J]. Biochim Biophys Acta, 2010, 1803 (1) :55-71.
|
|
[21] RAMIREZ T, LI YM, YIN S, et al. Aging aggravates alcoholic liver injury and fibrosis in mice by downregulating sirtuin 1 expression[J]. J Hepatol, 2017, 66 (3) :601-609.
|
|
[22] WU X, WU X, MA Y, et al. CUG-binding protein 1 regulates HSC activation and liver fibrogenesis[J]. Nat Commun, 2016, 7:13498.
|
|
[23] LAINE F, RUIVARD M, LOUSTAUD-RATTI V, et al. Metabolic and hepatic effects of bloodletting in dysmetabolic iron overload syndrome:A randomized controlled study in 274 patients[J]. Hepatology, 2017, 65 (2) :465-474.
|
|
[24] DAS SK, DESAULNIERS J, DYCK JR, et al. Resveratrol mediates therapeutic hepatic effects in acquired and genetic murine models of iron-overload[J]. Liver Int, 2016, 36 (2) :246-257.
|
|
[25] HUANG CK, YU T, de la MONTE SM, et al. Restoration of Wnt/beta-catenin signaling attenuates alcoholic liver disease progression in a rat model[J]. J Hepatol, 2015, 63 (1) :191-198.
|
|
[26] PASSINO MA, ADAMS RA, SIKORSKI SL, et al. Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR[J]. Science, 2007, 315 (5820) :1853-1856.
|
|
[27] LOPEZ-SANCHEZ I, DUNKEL Y, ROH YS, et al. GIV/Girdin is a central hub for profibrogenic signalling networks during liver fibrosis[J]. Nat Commun, 2014, 5:4451.
|
|
[28] ADACHI M, OSAWA Y, UCHINAMI H, et al. The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells[J]. Gastroenterology, 2007, 132 (4) :1434-1446.
|
|
[29] LI A, WANG J, WU M, et al. The inhibition of activated hepatic stellate cells proliferation by arctigenin through G0/G1phase cell cycle arrest:Persistent p27 (Kip1) induction by interfering with PI3K/Akt/FOXO3a signaling pathway[J]. Eur J Pharmacol, 2015, 747:71-87.
|
|
[30] MICHEAU O. Cellular FLICE-inhibitory protein:An attractive therapeutic target?[J]. Expert Opin Ther Targets, 2003, 7 (4) :559-573.
|
|
[31] PARK SJ, SOHN HY, YOON J, et al. Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells[J]. Cell Signal, 2009, 21 (10) :1495-1503.
|
|
[32] DURAN A, HERNANDEZ ED, REINA-CAMPOS M, et al.p62/SQSTM1 by binding to vitamin D receptor inhibits hepatic stellate cell activity, fibrosis, and liver cancer[J]. Cancer Cell, 2016, 30 (4) :595-609.
|
|
[33] GOURDIE RG, DIMMELER S, KOHL P. Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease[J]. Nat Rev Drug Discov, 2016, 15 (9) :620-638.
|
|
[34] ADACHI M, OSAWA Y, UCHINAMI H, et al. The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells[J]. Gastroenterology, 2007, 132 (4) :1434-1446.
|
|
[35] GAGGAR A, WEATHINGTON N. Bioactive extracellular matrix fragments in lung health and disease[J]. J Clin Invest, 2016, 126 (9) :3176-3184.
|
|
[36] CROSAS-MOLIST E, FABREGAT I. Role of NADPH oxidases in the redox biology of liver fibrosis[J]. Redox Biol, 2015, 6:106-111.
|
|
[37] OZAKI I, HAMAJIMA H, MATSUHASHI S, et al. Regulation of TGF-beta1-induced pro-apoptotic signaling by growth factor receptors and extracellular matrix receptor integrins in the liver[J]. Front Physiol, 2011, 2:78.
|
|
[38] DENG G, HUANG FZ, LIU XY, et al. Construction of recom binant adenovirus containing Akt and its expression in the liver of cirrhotic rats[J]. Chin J Gen Surg, 2008, 17 (7) :687-691. (in Chinese) 邓刚, 黄飞舟, 刘浔阳, 等.重组Akt腺病毒的构建及其在肝硬化大鼠肝脏中的表达[J].中国普通外科杂志, 2008, 17 (7) :687-691.
|
|
[39] VALDERRAMA-CARVAJAL H, COCOLAKIS E, LACERTE A, et al. Activin/TGF-beta induce apoptosis through Smad-dependent expression of the lipid phosphatase SHIP[J]. Nat Cell Biol, 2002, 4 (12) :963-969.
|
|
[40] KIM BC. FoxO3a mediates transforming growth factor-beta1-induced apoptosis in Fa O rat hepatoma cells[J]. BMB Rep, 2008, 41 (10) :728-732.
|
|
[41] PIAO SG, KANG SH, LIM SW, et al. Influence of N-acetylcysteine on Klotho expression and its signaling pathway in experimental model of chronic cyclosporine nephropathy in mice[J]. Transplantation, 2013, 96 (2) :146-153.
|
|
[42] BOSE SK, KIM H, MEYER K, et al. Forkhead box transcription factor regulation and lipid accumulation by hepatitis C virus[J]. J Virol, 2014, 88 (8) :4195-4203.
|
|
[43] van den BORNE SW, DIEZ J, BLANKESTEIJN WM, et al. Myocardial remodeling after infarction:The role of myofibroblasts[J]. Nat Rev Cardiol, 2010, 7 (1) :30-37.
|
|
[44] PRABHU SD, FRANGOGIANNIS NG. The biological basis for cardiac repair after myocardial infarction:From inflammation to fibrosis[J]. Circ Res, 2016, 119 (1) :91-112.
|
|
[45] MAZZOCCOLI G, de COSMO S, MAZZA T. The biological clock:A pivotal hub in non-alcoholic fatty liver disease pathogenesis[J]. Front Physiol, 2018, 9:193.
|
|
[46] SHIRASAKI T, HONDA M, SHIMAKAMI T, et al. Impaired interferon signaling in chronic hepatitis C patients with advanced fibrosis via the transforming growth factor beta signaling pathway[J]. Hepatology, 2014, 60 (5) :1519-1530.
|
|
[47] HARIHARAN N, MAEJIMA Y, NAKAE J, et al. Deacetylation of Fox O by Sirt1 plays an essential role in mediating starvation-induced autophagy in cardiac myocytes[J]. Circ Res, 2010, 107 (12) :1470-1482.
|
|
[48] SENGUPTA A, MOLKENTIN JD, PAIK JH, et al. Fox O transcription factors promote cardiomyocyte survival upon induction of oxidative stress[J]. J Biol Chem, 2011, 286 (9) :7468-7478.
|
|
[49] ZHANG K, LI L, QI Y, et al. Hepatic suppression of Foxo1and Foxo3 causes hypoglycemia and hyperlipidemia in mice[J]. Endocrinology, 2012, 153 (2) :631-646.
|
|
[50] NAKAE J, CAO Y, OKI M, et al. Forkhead transcription factor FoxO1 in adipose tissue regulates energy storage and expenditure[J]. Diabetes, 2008, 57 (3) :563-576.
|
|
[51] KAMEI Y, MIURA S, SUZUKI M, et al. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control[J]. J Biol Chem, 2004, 279 (39) :41114-41123.
|
|
[52] MILAN G, ROMANELLO V, PESCATORE F, et al. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy[J]. Nat Commun, 2015, 6:6670.
|
DownLoad: